A randomized controlled prospective study of Reyanning mixture in the treatment of mild novel coronavirus pneumonia (COVID-19)

Phase 4

Recruiting

• Conditions: ovel Coronavirus Pneumonia (COVID-19)

• Registration Number: ITMCTR2200006036
• Lead Sponsor: Jiujiang Hospital of Traditional Chinese Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

In accordance with the Novel Coronavirus Diagnosis and Treatment Protocol (Trial Version 9) issued by the National Health Commission Diagnosis of mild COVID-19; Signed informed consent.

Exclusion Criteria

1. Patients with normal, severe or critical type of NCOV infection; 2. Other lung diseases; 3. Patients with serious primary diseases such as heart, brain, liver, kidney and hematopoietic system; 4. Patients with basic lung diseases such as severe interstitial lung lesions confirmed by chest CT; 5. People who cannot cooperate in mental state, suffer from mental diseases, cannot control themselves and cannot express themselves clearly; 6. Allergic constitution (such as allergic to two or more drugs or food) or allergic history of this product and conventional treatment drugs; 7. Pregnant or lactating women.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ucleic acid turning negative time;Nucleic acid conversion rate;

Secondary Outcome Measures

Name	Time	Method
TCM syndrome scoring Scale;Factors of TCM diagnosis syndrome;Tongue and pulse survey of TCM;